Evidence map›Paper›PMID 22626818›Full record

ArticleJournal of the American Society of Nephrology : JASN2012

Recent peritonitis associates with mortality among patients treated with peritoneal dialysis.

Neil Boudville, Anna Kemp, Philip Clayton, Wai Lim, Sunil V Badve, Carmel M Hawley, Stephen P McDonald, Kathryn J Wiggins, Kym M Bannister, Fiona G Brown and 1 more

Registry-linked trialAbstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07113574 (Pharmacokinetics of Meropenem and Aztreonam After Intraperitoneal Administration Via Cycler-therapy in APD Patients Without Peritonitis), which is not on this map. Cited by 116 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07113574 phase2 / phase3completednot on this mapstarted 2021, after this paper: background citation

Pharmacokinetics of Meropenem and Aztreonam After Intraperitoneal Administration Via Cycler-therapy in APD Patients Without Peritonitis

TypeinterventionalSponsorKarl Landsteiner Insitute for Nephrology and Haemato-OncologyRan2021 to 2022Enrolled12ConditionsPeritoneal Dialysis Associated Peritonitis, Peritoneal Dialysis (PD), Peritoneal Dialysis, Peritoneal Dialysis, Continuous AmbulatoryArmsMeropenem 1000 mg, Aztreonam 2000 mg, automated peritoneal dialysis with following long time dwell, Sampling
3 · Its place in the literature

Who cites it

116 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Peritoneal Dialysis-RelatedClinical case reports · 2026
    Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

56 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Neil BoudvilleSchool of Medicine and Pharmacology, University of Western Australia, Perth, Australia. neil.boudville@uwa.edu.au
Anna Kemp
Philip Clayton
Wai Lim
Sunil V Badve
Carmel M Hawley
Stephen P McDonald
Kathryn J Wiggins
Kym M Bannister
Fiona G Brown
David W Johnson

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peritonitis is a major complication of peritoneal dialysis, but the relationship between peritonitis and mortality among these patients is not well understood. In this case-crossover study, we included the 1316 patients who received peritoneal dialysis in Australia and New Zealand from May 2004 through December 2009 and either died on peritoneal dialysis or within 30 days of transfer to hemodialysis. Each patient served as his or her own control. The mean age was 70 years, and the mean time receiving peritoneal dialysis was 3 years. In total, there were 1446 reported episodes of peritonitis with 27% of patients having ≥ 2 episodes. Compared with the rest of the year, there were significantly increased odds of peritonitis during the 120 days before death, although the magnitude of this association was much greater during the 30 days before death. Compared with a 30-day window 6 months before death, the odds for peritonitis was six-fold higher during the 30 days immediately before death (odds ratio, 6.2; 95% confidence interval, 4.4-8.7). In conclusion, peritonitis significantly associates with mortality in peritoneal dialysis patients. The increased odds extend up to 120 days after an episode of peritonitis but the magnitude is greater during the initial 30 days.

Indexed as

AgedAged, 80 and overAustraliaFemaleHumansLogistic ModelsMaleMiddle AgedNew ZealandPeritoneal DialysisPeritonitisTime Factors

Identifiers

PMID22626818
PMCPMC3402287

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.